Patients with chronic renal disease, and in particular chronic hemodialysis patients, are prone to various sleep disorders (SDs) that may affect their daily quality of life and contribute to increased their cardiovascular morbidity and mortality. [1] In comparison to the general population, the prevalence of SDs in patients with renal impairment is significantly increased due to the presence of usual risk factors such as age, gender, obesity and other factors specific to uremia and dialysis (anemia, uremic toxins, inflammation, side effects of drugs). [2] Sleep disorders appear very early during stages 1 and 2 of chronic renal failure and may worsen with decreasing renal function. [2] It's reported in other studies that up to 80% of dialysis patients complain of poor quality of sleep. [3] Insomnia, sleep apnea, restless legs syndrome and excessive daytime sleepiness are the most commonly reported SDs. [4] Besides, studies have shown that SDs may increase the risk of cardiovascular death in patients with chronic renal failure. [3] patiEnts and mEthodsThe study was designed as prospective observational single-center study conducted in the renal nephrology and renal transplant department of the Mohammed V Military Training Hospital in Rabat. All the 52 chronic hemodialysis patients were recruited for this study. The inclusion criteria were: adult dialysis patients (over 18 years of age), chronic hemodialysis patients for more than 1 year, three sessions per week, 4 h each. In the included patients, the SDs studied were: Insomnia, sleep apnea syndrome (SAS), restless legs syndrome and excessive daytime sleepiness.We conducted this study using a questionnaire in French and/or translated into dialectal Arabic, and based on the Insomnia Severity Index questionnaire which contains seven questions (difficulty falling asleep, difficulty staying asleep or Introduction: Sleep disorders (SD) are common in patients with renal failure, particularly in those on dialysis. This can impair their daily quality of life and worsen their cardiovascular prognosis. Objective: Our work aimed to describe the prevalence and risk factors of SDs among chronic hemodialysis patients in the Nephrology and Dialysis Department of the Rabat Military Hospital, Morocco. Patients and Methods: The trial was designed as a prospective single-center study and included all hemodialysis patients in the nephrology department of the Rabat Military Hospital. For each patient, we assessed four SDs: insomnia, sleep apnea, restless legs syndrome, and excessive daytime sleepiness. Results: We included 52 patients; the mean age of the patients was 50 ± 17 year (range 24-76); male:female ratio was 1.1. SDs were found in 40 patients with a predominance of insomnia and sleep apnea syndrome (SAS), and multivariate logistic regression was used to identify factors associated with different SD Insomnia was correlated with anemia, excessive daytime sleepiness, and inflammation; SAS was correlated with age ≥50 years, obesity and excessive daytime sleepiness. Restless legs s...
Brugada syndrome is a rare genetic disease of autosomal dominant inheritance with low penetrance, manifested by ST segment elevation at right precordial V1, V2 and V3 shunts, and a right bundle branch block aspect at the electrocardiogram. It exposes to a high risk of ventricular arrhythmia that can cause syncope (fainting) and even sudden death on a structurally normal heart. We report here the case of a 25-year-old patient with neuroleptic-induced Brugada syndrome. To our knowledge, this is the first reported case of neuroleptics-induced Brugada syndrome, Morocco. Therapeutic management is based on Amiodarone and beta-blockers. Regular monitoring of the ECG should be performed, however, on patients taking psychotropic drugs and also during associations.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.